UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 98

Sortiert nach

Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?

Haematologica (Roma), 2019-06, Vol.104 (6), p.1124

2019

Volltextzugriff (PDF)

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Blood, 2022-02, Vol.139 (5), p.732-747

2022

Volltextzugriff (PDF)

Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response

European journal of haematology, 2017-04, Vol.98 (4), p.371-377

2017

Volltextzugriff (PDF)

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

Blood, 2019-11, Vol.134 (20), p.1708-1711

2019

Volltextzugriff (PDF)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma

Cancers, 2021-12, Vol.13 (23), p.6089

2021

Volltextzugriff (PDF)

Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study "Cervax"

Frontiers in oncology, 2023-02, Vol.13, p.1133348-1133348

2023

Volltextzugriff (PDF)

Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging Behaviors

Frontiers in oncology, 2021-04, Vol.11, p.665736

2021

Volltextzugriff (PDF)

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi

Frontiers in oncology, 2021-12, Vol.11, p.789891-789891

2021

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in Combination with Radiotherapy as Salvage Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma: A retrospective Analysis in 12 Patients

Hematology reports, 2021-06, Vol.13 (2), p.9080-9080

2021

Volltextzugriff (PDF)

Role of Platelet Indices and Thrombopoietin (TPO) Serum Levels in the Differential Diagnosis of Thrombocytopenia

Blood, 2022-11, Vol.140 (Supplement 1), p.8406-8407

2022

Volltextzugriff (PDF)

Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study

Blood, 2018-08, Vol.132 (5), p.547-550

2018

Volltextzugriff (PDF)

Management of immune thrombocytopenia in elderly patients

European journal of internal medicine, 2018-12, Vol.58, p.70-76

2018

Volltextzugriff (PDF)

Carfilzomib, lenalidomide, dexamethasone ( KRD ) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi

British journal of haematology, 2024-06

2024

Volltextzugriff (PDF)

Teclistamab salvage therapy for multiple myeloma relapse after allogeneic hemopoietic stem cell transplant: A case report

American journal of hematology, 2024-01, Vol.99 (1), p.E29-E31

2024

Volltextzugriff (PDF)

Bayesian Analysis of TPO Levels in Immune Thrombocytopenia

Blood, 2018-11, Vol.132 (Supplement 1), p.1157-1157

2018

Volltextzugriff (PDF)

Autoimmune Cytopenias Following Alemtuzumab-Induced Renal Transplant: Clinical Features and Treatment Outcomes

Blood, 2018-11, Vol.132 (Supplement 1), p.2434-2434

2018

Volltextzugriff (PDF)

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Blood, 2019-11, Vol.134 (Supplement_1), p.3516-3516

2019

Volltextzugriff (PDF)

Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP)

Blood, 2019-11, Vol.134 (Supplement_1), p.2364-2364

2019

Volltextzugriff (PDF)

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience

Leukemia research, 2022-03, Vol.114, p.106803-106803, Article 106803

2022

Volltextzugriff (PDF)

Corrigendum to “Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience” [Leukemia Res. 114 (March 2022) 106803]

Leukemia research, 2022-04, Vol.115, p.106811-106811, Article 106811

2022

Volltextzugriff (PDF)

Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review

Journal of neurovirology, 2017-12, Vol.23 (6), p.908-912

2017

Volltextzugriff (PDF)

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(87)

Publikationsform

Artikel
(96)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(77)
Life Sciences & Biomedicine
(73)
Humans
(42)
Female
(19)
Male
(17)
Hematology
(16)
Adult
(15)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Middle Aged
(12)
Aged
(8)
General & Internal Medicine
(8)
Retrospective Studies
(8)
Toxicology
(8)
Italy - Epidemiology
(7)
Public, Environmental & Occupational Health
(7)
Animals
(6)
Italy
(6)
Neurology
(6)
Neurosciences & Neurology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma

Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study "Cervax"

Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging Behaviors

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi

Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab

Real‐world Outcomes of Relapsed/Refractory Diffuse Large B‐cell Lymphoma Treated With Polatuzumab Vedotin‐based Therapy

Immune Checkpoint Inhibitors in Combination with Radiotherapy as Salvage Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma: A retrospective Analysis in 12 Patients

Role of Platelet Indices and Thrombopoietin (TPO) Serum Levels in the Differential Diagnosis of Thrombocytopenia

Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study

Management of immune thrombocytopenia in elderly patients

Carfilzomib, lenalidomide, dexamethasone ( KRD ) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi

Teclistamab salvage therapy for multiple myeloma relapse after allogeneic hemopoietic stem cell transplant: A case report

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study

Bayesian Analysis of TPO Levels in Immune Thrombocytopenia

Autoimmune Cytopenias Following Alemtuzumab-Induced Renal Transplant: Clinical Features and Treatment Outcomes

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP)

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience

Corrigendum to “Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience” [Leukemia Res. 114 (March 2022) 106803]

Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review

Suchergebnisse filtern